Risk factors and risk reduction of breast and ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 15, Issue 1, 2003, Pages 63-68

  Brekelmans, Cecile T M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Ovarian cancer; Prevention; Review; Risk factors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CAROTENOID; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT;

ALCOHOL CONSUMPTION; BREAST CANCER; CANCER SURGERY; CHEMOPROPHYLAXIS; DIET; ENVIRONMENTAL FACTOR; EXERCISE; FAMILY HISTORY; FEMALE; GENE MUTATION; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; LACTATION; LIFESTYLE; MENARCHE; MENOPAUSE; ORAL CONTRACEPTION; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; REPRODUCTION; REVIEW; RISK FACTOR; SMOKING; VITAMIN INTAKE;

ALCOHOLISM; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; DIET; ENVIRONMENTAL EXPOSURE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIFE STYLE; OVARIAN NEOPLASMS; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 0037306973     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200302000-00010     Document Type: Review

References (61)

1. Lacey JV, Devesa S, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 2002; 39:82-88.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
3. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl):4-66.
4. The CHEK-2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31:55-59. •• This is the first study that finds evidence for a third breast cancer predisposition gene: mutations in CHEK-2 (also known as CHK-2), a gene involved in DNA repair, may account for approximately 1% of all breast cancers.
5. Chenevix-Trench G, Spurdle A, Gatei M, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002; 94:205-215. •• The first study demonstrating the high breast cancer risk of two recurrent ATM mutations, implying that genetic screening for ATM mutations may be worthwile.
6. De Jong MM, Nolte IM, te Meerman, et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 2002; 39:225-242.
7. Antoniou AC, Pharoah PDP, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86:76-83. • A segregation study investigating the genetic model that can best explain the residual non-BRCA1/2 familial aggregation of breast cancer.
8. Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T. Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int J Cancer 2002; 98:604-608.
9. Cohn BA, Cirillo PM, Christianson RE, et al. Placental characteristics and reduced risk of maternal breast cancer. J Natl Cancer Inst 2001; 93:1133-1140. • A cohort study with 40 years of follow-up that increases our understanding of the biology underlying the reduction in breast cancer risk by parity and age at first full-term pregnancy.
10. Vatten LJ, Romundstad PR, Odegard RA, et al. Alpha-foetoprotein in umbilical cord in relation to severe pre-eclampsia, birth weight and future breast cancer risk. Br J Cancer 2002; 86:728-731.
11. Sanderson M, Shu XO, Jin F, et al. Abortion history and breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2001; 92:899-905.
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 2002; 360:187-195. • A large collaborative re-analysis of 47 case-control and cohort studies quantifying the protective effect of breast feeding on the risk of breast cancer, taking account of other reproductive factors.
13. Marchbanks PA, McDonald JA, Wilson HG. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346:2025-2032. •• A large single study in 4575 women with breast cancer and 4682 controls between 35 and 64 years of age. The study was large enough to perform subgroup analyses with respect to race, age at initiation, duration and dosage of use and family history of breast cancer.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-333. •• The first randomized controlled trial that assessed the benefits and risks of HRT in healthy women.
15. Hulley S, Furberg C, Barrett-Connor E, et al., for the HERS Research Group. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen Replacement Study (HERS II) follow-up. JAMA 2002; 288:58-66.
16. Jacobs TW, Byrne C, Colditz G, et al. Pathologic features of breast cancers in women with prior benign breast disease. Am J Clin Pathol 2001; 115:362-369.
17. Terry P, Suzuki R, Hu FB, Wolk A. A prospective study of major dietary patterns and the risk of breast cancer. Cancer Epidemiol Biomarkers Prey 2001; 10:1281-1285.
18. Missmer SA, Smith-Warner SA, Spiegelman D, et al. Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. Int J Epidemiol 2002; 31:78-85.
19. Toniolo P, Van Kappel AL, Akhmedkhanov A, et al. Serum carotenoids and breast cancer. Am J Epidemiol 2001; 153:1142-1147.
20. Shrubsole MJ, Jin F, Dai Q, et al. Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Res 2001; 61:136-141.
21. Sellers TA, Kushi LH, Cerhan JR, et al. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 2001; 12:420-428.
22. Dai Q, Shu XO, Jin F, et al. Population-based case-control study of soyfood and breast cancer risk in Shanghai. Br J Cancer 2001; 85:372-378.
23. Horn-Ross PL, John EM, Lee M, et al. Phytoestrogen consumption and breast cancer risk in a multiethnic population: the Bay Area Breast Cancer Study. Am J Epidemiol 2001; 154:434-441.
24. Egan KM, Stampfer MJ, Hunter D, et al. Active and passive smoking in breast cancer: prospective results from the Nurses' Health Study. Epidemiology 2002; 13:138-145.
25. Friedenreich CM, Courneya KS, Bryant HE. Case-control study of anthropometric measures and breast cancer risk. Int J Cancer 2002; 99:445-452.
26. Hilakivi-Clarke L, Forsen T, Eriksson JG, et al. Tallness and overweight during childhood have opposing effects on breast cancer risk. Br J Cancer 2001; 85:1680-1684.
27. Swerdlow AJ, De Stavola BL, Floderus B, et al. Risk factors for breast cancer at young ages in twins: an international population-based study. J Natl Cancer Inst 2002; 21:1238-1246.
28. Friedenreich CM, Courneya KS, Bryant HE. Influence of physical activity in different age and life periods on the risk of breast cancer. Epidemiology 2001; 12:604-612.
29. Lee IM, Cook NR, Rexrode KM, Buring JE. Lifetime physical activity and risk of breast cancer. Br J Cancer 2001; 85:962-965.
30. Moradi T, Adami HO, Eckbom A, et al. Physical activity and risk for breast cancer: a prospective cohort study among Swedish twins. Int J Cancer 2002; 100:76-81.
31. Demers A, Ayotte P, Brisson J, et al. Plasma concentrations of polychlorinated biphenyls and the risk of breast cancer: a congener-specific analysis. Am J Epidemiol 2002; 155:629-635.
32. Hoyer AP, Gerdes AM, Jorgensen T, et al. Organochlorines, p53 mutations in relation to breast cancer risk and survival. A Danish cohort-nested case-control study. Breast Cancer Res Treat 2002; 71:59-65.
33. Davis S, Mirick DK, Stevens RG. Night shift work, light at night and risk of breast cancer. J Natl Cancer Inst 2001; 93:1557-1562. • A case-control study into the relationship between light at night and breast cancer, with detailed exposure information including sleeping habits, bedroom environment and graveyard shiftwork.
34. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 2001; 93:1563-1568. • A large cohort study with long follow-up into the relationship between rotating night shifts with at least three nights per month and breast cancer.
35. Davis S, Mirick DK, Stevens RG. Residential magnetic fields and the risk of breast cancer. Am J Epidemiol 2002; 155:446-454.
36. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38:99-166.
37. Berrino F, Capocaccia R, Esteve J, et al. Survival of cancer patients in Europe: The Eurocare-2 Study. IARC scientific publication no. 151. Lyon: IARC; 1999.
38. Antoniou AC, Gayther SA, Stratton J, et al. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000; 18:173-190.
39. Schildkraut JM, Cooper GS, Halabi S, et al. Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynaecol 2001; 98:85-90.
40. Ness RB, Cramer DW, Goodman MT, et al. Infertility, infertility drugs and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217-224. • A pooled analysis of eight case-control studies into the association between sub/ infertility and ovarian cancer that was able to differentiate between biological causes of infertility and the use of fertility drugs.
41. Walker GR, Schlesselman JJ, Ness RB. Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 2002; 186:8-14.
42. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001; 95:370-374.
43. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339:424-428.
44. Modan B, Hartge P, Hirsch-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:236-240. • A population-based case-control study investigating the association between oral contraceptive use and the risk of ovarian cancer, differentiating between carriers and non-carriers of a BRCA1 or BRCA2 mutation.
45. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285:1460-1465. • A large, prospective study with long follow-up investigating the association between oestrogen replacement therapy and ovarian cancer mortality in postmenopausal women.
46. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288:334-341. • A large cohort study into the risk of ovarian cancer after menopausal hormone therapy, differentiating between oestrogen-only and oestrogen-progestin formulas.
47. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94:497-504.
48. Cramer DW, Kuper H, Harlow BL, Titus-Ernstoff L. Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women. Int J Cancer 2001; 94:128-134.
49. Bosetti C, Negri E, Franchesci S, et al. Diet and ovarian cancer risk: a case-control study in Italy. Int J Cancer 2001; 93:911-915.
50. Fairfield KM, Hankinson SE, Rosner BA, et al. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 2001; 92:2318-2326.
51. Bertone ER, Newcomb PA, Willett WC, et al. Recreational physical activity and ovarian cancer in a population-based case-control study. Int J Cancer 2002; 99:431-436.
52. Rodriguez-Burford C, Barnes MN, Oelschlager DK, et al. Effects of non-steroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002; 8:202-209.
53. Friis S, Nielsen GL, Mellemkjaer L, et al. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 2002; 97:96-101.
54. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Aspirin and epithelial ovarian cancer. Prevent Med 2001; 33:682-687.
55. Meijers-Heijboer H, van Geel B, van Putten WLJ, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159-164. •• The first prospective evaluation of the risk of breast cancer after prophylactic mastectomy in confirmed carriers of a BRCA1 or BRCA2 gene mutation, all ascertained in one family cancer clinic.
56. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609-1615. •• The first prospective evaluation in 170 BRCA1/2 carriers investigating the incidence of breast and ovarian cancer after risk-reducing salpingo-oophorectomy.
57. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616-1622. •• A retrospective study with long follow-up in 551 BRCA1/2 carriers identified from 11 North American and European registries investigating the incidence of ovarian cancer after prophylactic oophorectomy.
58. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357:1467-1470.
59. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002; 20:3328-3343.
60. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 2001; 286:2251-2256. • Thr first study addressing the chemopreventive effect of tamoxifen in confirmed BRCA1 and BRCA2 carriers participating in the NSABP-P1 Breast Cancer Prevention Trial.
61. Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer 2002; 86:218-221.